Pharmabiz10d
Bayer announces positive results from phase III QUASAR study of aflibercept 8 mg in patients with macular edema following retinal vein occlusion
Bayer announced positive topline results from the global phase III QUASAR study evaluating the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein occlusion ...
PipelineReview.com11d
Aflibercept 8 mg met primary endpoint in phase III study and demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks ...